Skip to main content

Evaluation and Comparison of Existing Tests for Alpha-synuclein

Study Rationale:
An increase in the levels of alpha-synuclein -- a sticky protein that clumps in the brains of people with Parkinson's disease (PD) -- has been directly linked to an increased risk of Parkinson's. However, it remains unclear whether total alpha-synuclein levels in the cerebrospinal fluid or blood plasma can predict the onset or progression of PD or differentiate PD from other diseases related to alpha-synuclein. This is, in part, because the results of tests for alpha-synuclein vary greatly.

After alpha-synuclein is produced, the cell can make additional changes to the protein. These changes are known as post-translational modifications (PTMs). Existing tests for alpha-synuclein may be less effective because of PTMs, and for that reason, measurements of total alpha-synuclein levels in biosamples may be inaccurate.

Study Design:
In this study, we will use highly pure alpha-synuclein proteins as a standard to evaluate the effectiveness of four of the most commonly used total alpha-synuclein tests. We will assess whether these tests can detect different forms of naturally occurring alpha-synuclein, including those with PTMs.

Impact on Diagnosis/Treatment of Parkinson's Disease:
This study will explain inconsistencies in the results of alpha-synuclein testing in the human cerebrospinal fluid clarify the value of alpha-synuclein level as a potential diagnostic marker (objective measure) for PD.

Next Steps for Development:
Next, we will pursue the development of better tests capable of accurate measurement of total alpha-synuclein or the ratio of specific forms of alpha-synuclein to the total alpha-synuclein.


  • Hilal A. Lashuel, PhD

    Lausanne Switzerland

Discover More Grants

Search by Related Keywords

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.